Top-News
Biotechnologie USA

Sangamo Therapeutics Inc Aktie

Aktie
WKN:  936386 ISIN:  US8006771062 US-Symbol:  SGMO
0,7412 $
+0,00 $
0,00%
0,6556 € 20:43:38 Uhr
Depot/Watchlist
Aktienanzahl *
208,65 Mio.
Marktkapitalisierung *
142,07 Mio. €
Streubesitz
70,22%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 07.03.2025

Sangamo Therapeutics Inc News

28.04.25 - Businesswire
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine ...
04.04.25 - Der Aktionär
Sangamo‑Aktie schießt hoch: Deal mit Eli Lilly – die Details
03.04.25 - Businesswire
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Eli Lilly and Company (“Lilly”), allowing ...
17.03.25 - Businesswire
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and fourth quarter and full year 2024 financial results.
06.03.25 - Businesswire
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2024 ...
06.02.25 - Businesswire
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene ...
28.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO PR Newswire
08.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO PR Newswire
02.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO PR Newswire
19.12.24 - Der Aktionär
Sangamo: Das Comeback des Jahres – und es wird noch besser
19.12.24 - PR Newswire
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases PR Newswire
27.02.23 - PR Newswire
Thinking about buying stock in Broadmark Realty Capital, Seagen, Sangamo Therapeutics, Li Auto, or Bed Bath & Beyond?
Thinking about buying stock in Broadmark Realty Capital, Seagen, Sangamo Therapeutics, Li Auto, or Bed Bath & Beyond? PR Newswire
09.07.19 - Aktienwelt360
BB-Biotech-Beteiligung explodiert: Was bedeutet das für die Dividendenperle?
Die Aktie von BB Biotech (WKN: A0NFN3) wird von vielen Investoren sehr geschätzt. Einmal natürlich aufgrund der spannenden Dividendenpolitik. Denn die Beteiligungsgesellschaft ...
21.06.19 - PR Newswire
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019 PR Newswire
15.05.19 - PR Newswire
Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences
Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences Hemophilia A SB-525 gene therapy clinical data accepted for oral ...
10.05.19 - PR Newswire
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference PR Newswire
08.05.19 - PR Newswire
Sangamo Therapeutics Reports First Quarter 2019 Financial Results
Sangamo Therapeutics Reports First Quarter 2019 Financial Results Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time PR Newswire
01.05.19 - PR Newswire
Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast
Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast PR Newswire
15.04.19 - PR Newswire
Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy
Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy PR Newswire
04.04.19 - PR Newswire
Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock
Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire

Newssuche

Videos

newspaper
30.04.25 +22,47%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »